Monitoring azathioprine therapy in myasthenia gravis

Arnold S. Witte, David R. Cornblath, Norman J. Schatz, Robert P. Lisak

Research output: Contribution to journalArticlepeer-review

Abstract

Azathioprine (AZA) is used increasingly in the treatment of selected patients with myasthenia gravis (MG). The “usual” dose is 2 to 3 mg/kg/d, but guidelines do not exist to determine a specific dose for an individual patient. We reviewed our previously reported MG patients to determine what laboratory studies correlated with therapeutic efficacy. Among the studies examined, red cell mean corpuscular volume (RBC MCV) was the most useful: in 10 patients who responded to AZA, MCV increased by 15 ± 2 fl (mean ± SD), while in 6 nonresponders, MCV increased by only 4.5 ± 6 fl (p ≤ 0.01). RBC MCV may be helpful in monitoring AZA therapy in patients with MC.

Original languageEnglish (US)
Pages (from-to)1533-1534
Number of pages2
JournalNeurology
Volume36
Issue number11
DOIs
StatePublished - Nov 1986
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Monitoring azathioprine therapy in myasthenia gravis'. Together they form a unique fingerprint.

Cite this